PROQR THERAPEUTICS EO-04 (F:0PQ) — Market Cap & Net Worth
Market Cap & Net Worth: PROQR THERAPEUTICS EO-04 (0PQ)
PROQR THERAPEUTICS EO-04 (F:0PQ) has a market capitalization of $142.34 Million (€121.75 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #17943 globally and #1666 in its home market, demonstrating a -6.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PROQR THERAPEUTICS EO-04's stock price €1.56 by its total outstanding shares 105361064 (105.36 Million). Also see PROQR THERAPEUTICS EO-04 balance sheet assets for a full breakdown of the balance sheet.
PROQR THERAPEUTICS EO-04 Market Cap History: 2015 to 2026
PROQR THERAPEUTICS EO-04's market capitalization history from 2015 to 2026. Data shows change from $848.45 Million to $192.40 Million (-16.80% CAGR). Also see how efficiently does PROQR THERAPEUTICS EO-04 generate cash for how efficiently the company converts equity into cash flow.
PROQR THERAPEUTICS EO-04 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PROQR THERAPEUTICS EO-04's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PROQR THERAPEUTICS EO-04 (0PQ) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.13x
PROQR THERAPEUTICS EO-04's market cap is 13.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $843.77 Million | $1.33 Million | -$60.74 Million | 632.04x | N/A |
| 2022 | $383.58 Million | $3.59 Million | -$64.42 Million | 106.73x | N/A |
| 2023 | $215.19 Million | $6.51 Million | -$28.12 Million | 33.04x | N/A |
| 2024 | $320.51 Million | $18.91 Million | -$27.76 Million | 16.95x | N/A |
| 2025 | $208.79 Million | $15.91 Million | -$42.18 Million | 13.13x | N/A |
Competitor Companies of 0PQ by Market Capitalization
Companies near PROQR THERAPEUTICS EO-04 in the global market cap rankings as of September 19, 2026. Review PROQR THERAPEUTICS EO-04 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to PROQR THERAPEUTICS EO-04 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
PROQR THERAPEUTICS EO-04 Historical Marketcap From 2015 to 2026
Between 2015 and today, PROQR THERAPEUTICS EO-04's market cap moved from $848.45 Million to $ 192.40 Million, with a yearly change of -16.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €192.40 Million | -7.85% |
| 2025 | €208.79 Million | -34.86% |
| 2024 | €320.51 Million | +48.94% |
| 2023 | €215.19 Million | -43.90% |
| 2022 | €383.58 Million | -54.54% |
| 2021 | €843.77 Million | +94.60% |
| 2020 | €433.59 Million | -57.59% |
| 2019 | €1.02 Billion | -38.06% |
| 2018 | €1.65 Billion | +458.10% |
| 2017 | €295.75 Million | -46.51% |
| 2016 | €552.95 Million | -34.83% |
| 2015 | €848.45 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of PROQR THERAPEUTICS EO-04 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $142.34 Million USD |
| MoneyControl | $142.34 Million USD |
| MarketWatch | $142.34 Million USD |
| marketcap.company | $142.34 Million USD |
| Reuters | $142.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more